Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
17:485–487 © 1998 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume 17, 1998

Author Index

AIDS Clinical Trials Group Study 175
Virology Team, 203
Albert J, 214
Allan PW, 101
Anderson RD, 235
Anderson RW, 245
Archibald CP, 160
Arthur SP, 320
Ascher MS, 245

Baldwin JA, 275
Balzarini J, 120, 296
Barbosa P, 94
Barcellini-Couget S, 112
Bartholomew C, 167
Barton S, 239
Battegay M, 404
Beilke MA, 391
Benatti U, 189
Bentwich Z, 183
Bernard N, 171
Berry JM, 314, 320
Beyrer C, 73
Bianco N, 458
Biberfeld G, 262
Bindels P, 149
Bischofberger N, 120
Blatt SP, 345
Blattner WA, 167
Blaxhult A, 239
Bobkov AF, 97
Bobkova MR, 97
Boka-Yao A, 470
Bonard D, 470
Booth R, 275
Botts R, 314, 320
Bozek PS, 354
Braga C, 182
Brandi G, 189
Brandt CD, 69
Briggs W, 411
Brown JA, 9
Buckheit RW Jr, 101
Buckmaster PS, 1
Burke DS, 345
Burstein R, 183

Cagle HH, 275
Cahard D, 296
Cai B, 361, 368
Calvez V, 419
Cameron BA, 129
Casabianca A, 189
Casserella S, 227
Celentano DD, 73
Chiarantini L, 189
Cho Y-K, 58
Choi KW, 58
Choudhury I, 104
Christofalo B, 235
Chun J, 58
Chung RCY, 345
Cimoch PJ, 227
Claxton AJ, 51
Cleghorn FR, 167
Clotet B, 239
Cocho G, 385
Cohn DL, 345
Collier AC, 303
Colón HM, 477
Coombs RW, 303
Corey L, 303
Coscarelli A, 433
Coudronnière N, 17
Coulibaly IM, 470
Courpotin C, 92
Coutellier A, 419
Coutinho R, 149
Crane L, 137
Cranston B, 167
Crnich C, 196
Cucchiarini M, 112

Dabis F, 171, 470
DaCosta MM, 314, 320
Darragh TM, 314, 320
David C, 17
De Clercq E, 120, 296
De Flora A, 189
de Perez GE, 458
de Sá M, 91
de Wit TR, 149
Dean M, 181
Debré P, 419
DeLeys RJ, 91
Dequae-Merchadou L, 171
Devaux C, 17
Devito C, 156
Diaz FG, 137
Dickinson BP, 376
Do NH, 283
Doglio A, 112
Dominguez V, 385
Doorly R, 149
Dormont D, 92
D'Souza MP, 27
Dube S, 458
Dudek FE, 1
Dunkle LM, 235
Dwyer JM, 129
DYSCER-CI Group, 470

Egger M, 404
Erfle V, 120
Estrada JL, 385
EuroSIDA Study Group, 239
Evers S, 143
Everson-Mays RE, 354

Fanning TR, 35
Faruki H, 42
Feingold KR, 51
Fenaughty AM, 275
Fessler RD, 137
Ffrench RA, 129
Finlinson HA, 477
Fisher DG, 275
Fitch WM, 58
Flanagan A, 327
Flanigan TP, 376
Flynn C, 253
Fontanet A, 149
Ford K, 269
Franceschi S, 182
Fraternale A, 189
Fridey J, 332
Fuchs D, 291
Fukuda Y, 209

Ganz PA, 433
Gardner LI, 345
Gevorkian G, 385
Gialeraki A, 181
Gisslén M, 291

Glaser CA, 79
Glynn S, 332
Godoy C, 262
Goebel F-D, 120, 239
Goldberg M, 120
Goldstein R, 361, 368
Gorochov G, 419
Govezensky T, 385
Graham NMH, 253
Grant P, 220
Gras GS, 92
Grate L, 398
Griffy KG, 227
Gross M, 368
Grossman Z, 450
Grotemeyer K-H, 143
Groupe d'Epidémiologie Clinique du SIDA en Aquitaine, 171
Guyot L, 137

Haesevelde MV, 91
Hagberg L, 291
Hansson P, 214
Hardy WD, 339
Harris RW, 345
Harrison SH, 345
Hartmann K, 120
Hashido M, 95
Hatzakis A, 181
Haworth SJ, 235
Hayakawa T, 209
Heeren T, 361, 368
Hendrix CW, 345
Hengst J, 458
Herberman RB, 450
Herson S, 419
Hervé F, 92
Hingson R, 368
Hinkula J, 156
Hirn M, 17
Hirschel B, 239
HIV Epidemiology Research Study (HERS) Group, 253
Hodge MJ, 73
Hogeboom CJ, 314
Holland GN, 339
Holly EA, 314, 320
Holmberg S, 253
Holy A, 120
Hoover EA, 1
Houchens R, 35
Howcroft TK, 9
Hughes M, 203
Husstedt Ingo-W, 143

Ikezoe T, 380
Inouye S, 95
Intrator N, 450
Iribarren C, 51
Ives DV, 339

Jack N, 167
Jacobs DR Jr, 51
Jaffe HS, 339
Japa S, 391
Jay N, 314, 320
Jindrich J, 120
Jittiwutikorn J, 73
Johnson M, 339
Journot V, 171
Jung D, 227

Kalinkovich A, 183
Kalish LA, 180
Kam KM, 185
Kang C, 58
Kang MR, 58
Kaplan EH, 465
Karafoulidou A, 181
Karmochkine M, 419
Katlama C, 239
Katzenstein DA, 203
Kaufman TE, 69
Kawana T, 95
Kedem E, 465
Keiser P, 220
Kelly M, 129
Kemper CA, 339
Kenyon E, 94
Khanina TA, 97
Kilby JM, 46
Killewo J, 262
Kilpatrick R, 94
Kim D-G, 58
Kim JM, 58
Kim S, 58
Kim SH, 58
Kim Y-B, 58
Kim Y-K, 58
Kingsley LA, 42
Kitchen VS, 327
Koumbarelis E, 181
Kraft W, 120
Kramer F, 339
Kuffer M, 120
Kully C, 404
Kuppermann BD, 339
Kwesigabo G, 262

La Ruche G, 470
La Vecchia C, 182
Lafazia L, 376
Lalezari JP, 339
Larralde C, 385
Lasfargues G, 92
Lavalle C, 385
Lavelle J, 227
Lee FK, 95
Lee HJ, 58
Lee I-s, 58
Lee JS, 58
Lee SS, 185
Lefebvre J-C, 112
Leibowitz MJ, 104
Lenderking WR, 361, 368
Leon-Ponte M, 458
Levi M, 156
Lewis RA, 339
Libonatti O, 156
Link H, 214
Lloyd A, 129
Long T, 196
Love J, 458
Loveland L, 94
Luban N, 332
Lundgren JD, 239
Lüttmann S, 143

Mabondzo A, 92
Macotela Y, 385
Magnani M, 189
Maloney EM, 167
Mandalaki T, 181
Manns A, 167
Marimoutou C, 171
Markson LE, 35
Marrero CA, 477
Martin C, 214
Maso LD, 182
Masso F, 385
Matos TD, 477
Matsui S, 380
Mayer KH, 361, 368
Mayers DL, 345
Mbena E, 262
McGuigan C, 296
McKinley GF, 339
Medina RDF, 156
Meléndez M, 477
Merigan TC, 203
Messele T, 149
Mhalu F, 262
Military Medical Consortium for Applied Retroviral Research, 345
Millo E, 189
Mitchell TW, 1
Miyata K, 95
Miyoshi I, 380
Moore J, 253
Morgan OStC, 167
Muneishi H, 380
Muñoz A, 477
Murphy EL, 332

Naesens L, 120
Nagata Y, 95
Nahmias AJ, 95
Narwa R, 92
Nasioulas G, 181
Nelson KE, 73
Nelson R, 339
Newman TB, 79
Norkrans G, 291
Norris AE, 269
Northfelt DW, 339

O'Donnell RM, 69
Ofner M, 160
O'Leary JF, 433
Onoue O, 380
O'Shaughnessy MV, 160

Pacheco M, 385
Palefsky JM, 314, 320
Panther LA, 303
Paraskevis D, 181
Parizot C, 419
Parnet-Mathieu F, 92
Patrick DM, 160
Pedersen C, 239
Pehrsson P, 214
Perdue BE, 354
Perneger TV, 442
Perrin L, 442
Peter JB, 186
Petersen L, 433
Pfluger D, 404
Phillips AN, 239
Pi J-T, 203
Poiesz BJ, 458
Pollack S, 465
Pollard R, 227
Pooyan S, 104

Qian D, 411

Rabkin JG, 179
Rabson AB, 104
Ragni MV, 42
Rakusan TA, 69
Ralston ML, 314, 320
Ramon R, 470
Re AL, 182
Reichelt D, 143
Reingold A, 79
Rekart ML, 160
Remafedi G, 83
Retrovirus Epidemiology Donor Study (REDS) Investigators, 332
Rey D, 203
Reyes JC, 477
Rich JD, 376
Rivera S, 411
Robles RR, 477
Rodgers-Johnson P, 167
Rodriguez H, 385
Roques P, 92
Rose LM, 101
Rosenstein IJ, 327
Ruby AE, 339
Rudin C, 404

Saarloos M-N, 196
Sacher R, 332
Safrin S, 79
Sahai H, 477
Sahlu T, 149
Saifuddin M, 196
Saillour F, 171
Saito H, 209
Salgado A, 296
Saman E, 91
Sandstrom A, 262
Sankov MN, 97
Sattler FR, 411
Sawada T, 380
Saxena ES, 69
Scarfì S, 189
Schechter MT, 160
Schoenbaum E, 253
Schreiber G, 332
Schuman P, 253
Seage GR III, 368
Seage III GR, 361
Secrist JA III, 101
Sever JL, 69
Shannon WM, 101
Shearer WT, 180
Sheppard HW, 245
Shin Y-O, 58
Sidney S, 51
Simon GL, 339
Singer DS, 9
Sison AV, 69
Skiest DJ, 220
Smith J, 332
Smith JR, 327
Sobel J, 137
Solomon L, 253
Sönnerborg A, 214
Sonoda S, 95
Spaulding A, 376
Spear GT, 196
Stafford MK, 327
Stagg RJ, 339
Stein M, 253
Stein Stanley, 104
Stein Steven, 104
Stevens S, 275
Strathdee SA, 160
Sullivan LM, 424
Sutherland D, 160
Svennerholm B, 291
Swiss Collaborative HIV and Pregnancy Study (SCHPS), 404
Swiss HIV Cohort Study, 442
Swiss HIV Cohort Study (SHCS), 404
Sylla-Koko F, 470
Szuba MJ, 137

Tabereaux PB, 46
Taguchi H, 380
Takamatsu J, 209
Tanaka S, 380
Taniguchi T, 380
Tao G, 83
Tarnowski TL, 227
Taylor-Robinson D, 327
Terskikh VA, 97
Thormar H, 296
Toyoda H, 209
Tran SD, 283
Trickett AE, 129
Truong HT, 283
Turner BJ, 35

Urassa W, 262

Van de Perre P, 184
Van Eynde G, 91
Van Geel A, 91
Vanderborght B, 91
Vatnik N, 450
Vazquez J, 137
Velázquez S, 296
Vella S, 239
Vinson DG, 391
Viveros M, 385
Vyas GN, 27

Wagner GJ, 179
Wagner KF, 345
Wall S, 262
Wang J, 104
Ward H, 327
Watanabe K, 332
Weber J, 327
Wedgwood O, 296
Weidle PJ, 354
Weinberg DV, 339
Weisman Z, 183
Weisser M, 404
Weissman JS, 424
Welffens-Ekra C, 470
Welles SL, 51
Whalen LR, 1
White EL, 101
Wigzell H, 156
Williams AB, 283
Wilson IB, 424
Winters M, 203
Wold C, 361, 368
Wolitz RA, 339
Women and Infants Transmission Study Group, 180
Wong KH, 185
Wong R, 227
Wright D, 332
Wu AW, 433

Yang G, 27
Yang J-M, 58
Yarnold CJ, 296
Yeneneh H, 149
Yerly S, 442
Yoon K, 58
Youle M, 339

Zeh JE, 303
Zimmerman PA, 180
Zverev SY, 97

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
17:488–492 © 1998 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 17 1998

Subject Index

Abidjan, HIV counseling and testing of women in, 470
Acyclic nucleoside phosphonates, efficacy against FIV, 120
Adolescents, alcohol use and condom use in, 269
Africa
  declining HIV-1 infection in women of, 262
  HIV counseling and testing of women in, 470
  standard values of T-lymphocyte subsets in (letter), 183, 184
AIDS
  in bisexual men, 361
  catheter infections and, 220
  CD4 decline in presence of homeostasis in, 245
  cidofovir for relapsing cytomegalovirus retinitis of, 339
  cost of care and outcome of, 424
  GB virus C/hepatitis G virus coinfection and, 209
  health services use by urban women at risk for, 253
  with heterosexual transmission in hemophilic patients, 42
  surveillance data, computational methods for reporting delay adjustment in (letter), 182
AIDS dementia, antiretroviral treatment for, 143
AIDS Malignancy Conference, Second National, A1
Alcohol use
  social context of, 368
  in urban minority youth, 269
Allele frequency, of CCR5 mutant chemokine receptor in Greek Caucasians (letter), 181
Ambulatory care
  medication costs for, 354
  repeated use by HIV-infected patients, 35
Anal cancer
  in HIV-positive and -negative homosexual and bisexual men, 320
  in HIV-positive and -negative homosexual men, 314
Anal squamous intraepithelial lesions
  in HIV-positive and -negative bisexual men, 320
  in HIV-positive and -negative homosexual men, 314, 320
Animal exposure, *Cryptosporidium* infection and in HIV-infected patients, 79
Animal model, of axonal sprouting in hippocampus with FIV, 1
Anti-CD4 monoclonal antibody, HIV-1 resistant to, 17
Antiretroviral therapy
  in AIDS dementia, 143
  HIV-1 viral load without, 291
  landmark changes in and medication costs, 354
  survival and, 239
Apoptosis
  in CD4 decline in AIDS, 245
  viral load and susceptibility of PBMCs to, 419
Argentina, HIV-1 V3 subtype seroreactivity in, 156
Asia, risk factors for HIV seropositivity in drug users in, 283
Autologous lymphocyte infusion, in HIV infection, 129
Axonal sprouting, in hippocampus of cats with FIV, 1
Azidothymidine homodinucleotide, in murine AIDS inhibition, 189
$AZTp_2AZT$, in murine AIDS inhibition, 189

Biologic markers, of HIV-1 infection, 303
Biotin, in HIV-1 replication inhibition, 104
Bisexual men
  adolescent, HIV prevention interventions for, 83
  anal squamous intraepithelial lesions in, 320
  unsafe sex in, 361
Body composition, HIV RNA levels and, 411
Body mass index, HIV RNA levels and, 411
Boston
  cost of AIDS care and outcome in HMOs and FFS systems in, 424
  social context of drinking, drug use, and unsafe sex in, 368

Calcium abnormalities, in HTLV-I and HTLV-II infection, 332
Canada, needle exchange program attendance by drug users in, 160
Catheter infections, AIDS and, 220
CCR5
  mutant chemokine receptor, allele frequency of in Greek Caucasians (letter), 181
  vertical transmission of (letter), 180
CD4 antigen, in HIV-1 transcription, 17
CD4 cell count
  in HIV outcome predictions, 442
  interpreting values in different HIV-infected populations (letter), 185
  unintegrated circular HIV-1 DNA in peripheral mononuclear cells and decline in, 303
CD4 cells
  downmodulation by Nef expression, 112
  HIV cytopathicity and decline in, 245
  standard values in subsets of in African populations (letter), 183, 184
CD25 cells, retroviral transfer to target cells, 196
CD8 subsets, standard values of in African populations (letter), 183, 184
Cellular activation, by retrovirus, 196
Central venous catheters, AIDS and infections with, 220
Cerebrospinal fluid
  mononuclear cell counts and HIV-1 RNA levels of, 214
  stavudine penetration into, 235
  viral load without antiretroviral treatment, 291
Chemotherapy, for FIV, 120
Children, Epstein-Barr virus DNA and HIV status in, 69
Chlamydia, in pregnant Japanese women with HTLV-I (letter), 95
Cholesterol, HIV infection and in high-risk men, 51
Cidofovir, for relapsing cytomegalovirus retinitis of AIDS, 339
Cocaine, needle exchange program attendance for, 160
Codon 215 mutation, in plasma RNA, 203
Cohort site study, of HIV natural history in Ethiopia, 149
Combination therapy
  for murine AIDS, 189
  pharmacokinetics of in HIV-infected subjects, 227
Condom use
  in bisexual men, 361
  in Native American drug users, 275
  in urban minority youth, 269
Corticosteroids, diabetes mellitus and, 46

Counseling, for women of childbearing age, 470
Creatine kinase, in HTLV-I and HTLV-II infection, 332
Cryptococcal meningitis, managing elevated intracranial pressure in, 137
Cryptosporidium infection, animal exposure and in HIV-infected patients, 79
Cytokines, in HIV-associated wasting and HIV RNA levels, 411
Cytology, anal
  of anal squamous intraepithelial lesions in homosexuals, 314
  in HIV-positive and -negative homosexual and bisexual men, 320
Cytomegalovirus infection
  cidofovir for relapsing retinitis of, 339
  predictive factors of and impact on survival, 171
Cytopathic hypothesis, of CD4 decline in AIDS, 245

Dentate gyrus, in cats with FIV, 1
Diabetes mellitus, preexisting versus drug-associated, 46
Didanosine
  diabetes mellitus and, 46
  pharmacokinetics in HIV-infected subjects, 227
Dideoxynucleoside analog derivatives, in Visna virus inhibition, 296
Disease progression
  of anal squamous intraepithelial lesions, 314
  improving prediction of, 442
  megestrol use in HIV-positive men and (letter), 179
  pregnancy and, 404
  unintegrated circular HIV-1 DNA in peripheral mononuclear cells and, 303
  zidovudine use and, 345
DNA analysis
  of endemic HTLV-IIB infection in Venezuelan Indians, 458
  in HIV-1 strain HXB2, 398
Drug treatment programs, risk factors for HIV seropositivity in drug users in, 283
Drug use
  HIV-1 infection epidemiology and, 73
  in prison population, 376
  social context of, 368
Drug users. *See* Injection drug users
Dysplasia
  in HIV-positive and -negative homosexual and bisexual men, 320
  in HIV-positive and -negative homosexuals, 314

Emergency department, repeated use by HIV-infected persons, 35
Encephalopathy, antiretroviral treatment for, 143
Endemic infection, HTLV-IIB, 458
Enzyme-linked immunoabsorbent assay, in study of HIV-1 V3 subtype seroreactivity, 156
Eosinophil count, for HTLV-I and HTLV-II infection, 332
Epidemiology
  of endemic HTLV-IIB infection in Venezuelan Indians, 458
  of HIV-1 in opiate users of Thailand, 73
  of plantar verrucae in HIV infection (letter), 94
  of serum total cholesterol and HIV infection, 51
  zidovudine benefit in, 345
Epstein-Barr virus DNA, in infant, child, and adult blood by age and HIV status, 69
Escaped mutations, resistant to anti-CD4 monoclonal antibody, 17
Ethiopia
  cohort site study of HIV natural history in, 149
  HIV infection incidence in immigrants from, 465
Ethnic minorities. *See also specific ethnic groups*
  alcohol use and condom use in, 269
  HIV-1 infection epidemiology with opiate use in, 73
Event-related potentials, in antiretroviral treatment for AIDS dementia, 143

Fee-for-service systems, cost of AIDS care and outcome in, 424
Feline immunodeficiency virus
  acyclic nucleoside phosphonates efficacy against, 120
  axonal sprouting of hippocampus in, 1
FIV. *See* Feline immunodeficiency virus
FPMPA, efficacy against FIV, 120
France, predictive factors of cytomegalovirus infection and impact on survival in, 171

Ganciclovir, pharmacokinetics of in HIV-infected subjects, 227
GB virus C, in HIV infection course, 209
Glycoprotein GPIIIa, human platelet, antigenic homology of, 385
GP41, HIV-1, antigenic homology of, 385
Greek population, allele frequency of CCR5 mutant chemokine receptor in (letter), 181

Health care costs
  for ambulatory HIV-infected patients, 354
  outcome of AIDS and, 424
Health maintenance organizations, cost of AIDS care and outcome in, 424
Health outcomes. *See* Outcome
Health services
  accessibility to by HIV-infected patients, 35
  use of by urban women at risk for HIV-1 infection, 253
Health status, measurement of, 433
Health-related quality of life, better understanding of, 433
Hemophilia
  GB virus C/hepatitis G virus coinfection in, 209
  heterosexual HIV-1 transmission with, 42
Hepatitis G virus, in HIV infection course, 209
Heroin users, HIV-1 infection epidemiology and, 73
Herpes simplex virus, in pregnant Japanese women with HTLV-I (letter), 95
Heterosexual transmission, in hemophilic patients, 42
Heterosexuals, unsafe sex in, 361
High-risk male cohort, serum total cholesterol and HIV infection in, 51
Hippocampus, axonal sprouting in FIV, 1
HIV. *See* HIV-1 infection; Human immunodeficiency virus
HIV clinic, severe hypoglycemia in, 46
HIV counseling, in women of childbearing age, 470
HIV-1 infection
  declining prevalence in young women in Tanzania, 262
  health services use by urban women at risk for, 253
  with HTLV-I/II coinfection, 391
  monophyletic clade in Korean cases of, 58
  neutralizing antibodies against, 27
  outcome prediction of, 442
  peripheral mononuclear cells and, 303
  replication inhibition by tat RNA-binding domain peptide analog, 104
  subtype B glycoprotein (letter), 91
  transmission and viral load in hemophilic patients, 42
  unintegrated circular HIV-1 DNA in, 303
  V3 subtypes, seroreactivity to, 156
  viral load of without antiretroviral treatment, 291
HIV Overview of Problems-Evaluation System (HOPES), versus Medical Outcomes Study HIV Health Survey (MOS-HIV), 433
HIV-1 reverse transcriptase, codon 215 mutation of, 203
HIV RNA
  declining viral loads of in United States (letter), 186
  HIV-associated wasting and levels of, 411
HIV-1 RNA
  cerebrospinal fluid levels of, 214

in HIV outcome prediction, 442
unintegrated circular HIV-1 DNA in peripheral mononuclear cells and high plasma levels of, 303
HIV seropositivity
in incarcerated population, 376
in injecting drug users in Puerto Rican shooting galleries, 477
HIV-1 strain HXB2, potential SECIS elements in, 398
HIV tat protein, for transactivation and repression of transcription, 9
HIV testing
mandatory, in prison populations, 376
in women of childbearing age, 470
HIV-1 transcription, anti-CD4 monoclonal antibody inhibiting, 17
HIV-associated wasting, HIV RNA levels and, 411
HIV-infected cells, polyamine pools in, 101
HIV-infected patients, repeated emergency department use by, 35
HIV-neutralizing antibodies, determined by VTR amplification, 27
HLA-DR, retroviral transfer to target cells, 196
Homosexual men
adolescent, HIV prevention interventions for, 83
anal squamous intraepithelial lesions in, 314, 320
social context of unsafe sex in, 368
Host protein, transfer to target cells, 196
Host T-cell, membrane HLA-DR and CD25 transfer to target cells, 196
HTLV. *See* Human T-cell lymphotropic virus
Human immunodeficiency virus
autologous lymphocyte infusion effect on, 129
conservation of total T-cell counts during, 450
cytopathicity and CD4 decline in AIDS, 245
diabetes mellitus and, 46
early stage natural history with zidovudine use, 345
GB virus C/hepatitis G virus coinfection and, 209
incidence in Ethiopian immigrants to Israel, 465
in injection drug users, 160
natural history of in Ethiopia, 149
pregnancy and course of, 404
replication late stage replication of, 112
serum total cholesterol and in high-risk men, 51
transmission model in gay and bisexual male adolescents, 83
Human monocyte-derived macrophages, HIV-1 transmission and maternal antibody titers (letter), 92
Human papillomavirus
in HIV-positive and -negative homosexual and bisexual men, 320
in HIV-positive and -negative homosexuals, 314
Human T-cell lymphotropic virus
type I
laboratory test values for, 332
myelopathy/tropical spastic paraparesis incidence with, 167
in patients with STDs in Russia (letter), 97
in pregnant Japanese women (letter), 95
prevalence in leprosy patients, 380
virus expression with HIV-1 coinfection, 391
type II
laboratory test values for, 332
virus expression with HIV-1 coinfection, 391
type IIB, endemic, in Venezuelan Indians, 458
Hydrocephalus, in cryptococcal meningitis, 137
Hypoglycemia, in HIV clinic, 46

Immune activation, in CD4 decline, 245
Immunocompetence, autologous lymphocyte infusion effect on, 129
Immunodeficiency, murine retrovirus-induced, 189
Immunology, HIV-1 reverse transcriptase codon 215 mutation in, 203
Immunotherapy, adoptive cellular, autologous lymphocyte infusion in, 129
Incidence, in Ethiopian immigrants to Israel, 465
Infants, Epstein-Barr virus DNA and HIV status in, 69
Inflammatory response, to nonoxynol-9, 327
Injection drug users
health services use by, 253
needle exchange program attendance by, 160
in prison population, 376
risk behavior, HIV seropositivity and tuberculosis infection in, 477
risk factors for HIV seropositivity in, 283
sex partners in, 275
Integrin β_3, antigenic homology of, 385
Interleukin-2 receptor, in HLA-DR and CD25 transfer, 196
Intervention, for HIV prevention in gay and bisexual male adolescents, 83
Intracranial pressure, elevated, in cryptococcal meningitis, 137
Intraepithelial neoplasia, in HIV-positive and -negative homosexual and bisexual men, 320
Israel, HIV infection incidence in Ethiopian immigrants to, 465
Ivory Coast, HIV counseling and testing of women in, 470

Jamaica, HTLV-I-associated myelopathy/tropical spastic paraparesis in, 167
Japan
GB virus C/hepatitis G virus coinfection in hemophilia patients in, 209
HTLV-I infected women in (letter), 95
HTLV-I prevalence in leprosy patients in, 380

Kagera region, declining HIV-1 infection in women of, 262
Korea, monophyletic clade in HIV-1 cases in, 58

Laboratory tests
for HIV-neutralizing antibodies, 27
to improve clinical outcome predictions, 442
values for HTLV-I and HTLV-II infection, 332
Lactic dehydrogenase, in HTLV-I and HTLV-II infection, 332
Lactobacillus species, vaginal microbicide for, 327
Lentivirus, axonal sprouting in hippocampus and, 1
Leprosy patients, HTLV-I prevalence in, 380
Letters to editor
allele frequency of the CCR5 mutant chemokine receptor in Greek Caucasians, 181
CCR5 HIV-1 vertical transmission, 180
comparison of computational methods for reporting delay adjustment in AIDS surveillance data, 182
declining HIV RNA viral loads in the United States, 186
effect on serologic reactivity of P-to-W substitution in the apex of the V3 loop of the HIV-1 subtype B glycoprotein, 91
epidemiology of plantar verrucae in HIV-infected individuals, 94
herpes simplex virus types 1 and 2, chlamydia, syphilis, and toxoplasma in pregnant Japanese women with HTLV-I, 95
interpretation of $CD4^+$ T-lymphocyte values in different HIV-infected populations, 185
lack of correlation between vertical transmission of HIV-1 and maternal antibody titers against autologous virus in human monocyte-derived macrophages, 92
standard values of T-lymphocyte subsets in Africa, 183
standard values of T-lymphocyte subsets in Africa: author's reply, 184
study of HTLV-I prevalence in patients with sexually transmitted diseases in Perm and Ekaterinburg, Russia, 97
testosterone, illness progression, and megestrol use in HIV-positive men, 179
Leukapheresis, immunocompetence and, 129
Longitudinal study, of cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment, 291

Lymphocytes
count, for HTLV-I and HTLV-II infection, 332
depletion of in HIV infection, 450
dynamics of in CD4 decline in AIDS, 245
redistribution of in HIV infection, 450
Lymphoproliferative interstitial pneumonia, Epstein-Barr virus DNA and, 69

Mandatory testing, in prison population, 376
Masked aryloxyaminoacylphosphoramidate (dideoxy)nucleoside analogs, in Visna virus inhibition, 296
Maternal antibodies, vertical transmission of HIV-1 and (letter), 92
Mean corpuscular volume, in HTLV-I and HTLV-II infection, 332
Medicaid, for HIV-infected patients, 35
Medical costs. *See* Health care costs
Medical Outcomes Study HIV Health Survey (MOS-HIV), versus HIV Overview of Problems-Evaluation System (HOPES), 433
Medication costs, for ambulatory HIV-infected patients, 354
Megestrol acetate
diabetes mellitus and, 46
testosterone and illness progression and (letter), 179
Meningitis, managing elevated intracranial pressure in, 137
Minority groups. *See* Ethnic minorities; *specific groups*
Molecular epidemiology
of endemic HTLV-IIB infection in Venezuelan Indians, 458
of *nef* gene, 58
Molecular mimicry, of HIV-1 GP41 and human platelet glycoprotein GPIIIa, 385
Monoclonal antibody, HIV-1 resistant to, 17
Mononuclear cell counts, cerebrospinal fluid HIV-1 RNA levels and, 214
Monophyletic clade, in Korean HIV-1, 58
Mortality, improving prediction of, 442
Mossy fibers, in cats with FIV, 1
mRNA secondary structure, in HIV-1 strain HXB2, 398
Murine AIDS, inhibition by azidothymidine homodinucleotide, 189
Mutation, reverse transcriptase codon 215, 203
Myelopathy, incidence with HTLV-I in Jamaica and Trinidad, 167

Native Americans, sex partners in, 275
Needle exchange program, attendance of in Vancouver, Canada, 160
nef gene
expression of in CD4 downmodulation, 112
phylogenetic analysis of, 58
Nonxynol-9, safety study of as vaginal microbicide, 327
Nucleoside analog drugs, survival and, 239

Opiate users, HIV-1 infection epidemiology in, 73
Ornithine decarboxylase, in HIV-infected cells, 101
Outcome
AIDS care costs and, 424
improving predictions of, 442

Paraparesis, HTLV-I-associated tropical spastic, 167
Pathogenesis, CD4 decline and, 245
Pentamidine, diabetes mellitus and, 46
Peptides, HIV-1 V3 subtype A to H, 156
Peripheral blood mononuclear cells
susceptibility to apoptosis and plasma HIV load, 419
unintegrated circular HIV-1 DNA in, 303
Pharmacokinetics, of oral ganciclovir and combined therapy, 227
Phylogenetic analysis, of *nef* gene, 58
Plantar verrucae, in HIV-infected individuals (letter), 94
Plasma RNA, HIV-1 reverse transcriptase codon 215 mutation in, 203
Platelets
count, for HTLV-I and HTLV-II infection, 332
glycoprotein GPIIIa, antigenic homology of, 385
PMEA, efficacy against FIV, 120
Polyamine pools, in HIV-infected cells, 101
Polymerase chain reaction amplification
in determining HIV-neutralizing antibodies, 27
for EBV DNA, 69
of endemic HTLV-IIB infection in Venezuelan Indians, 458
in HIV-1 RNA level analysis, 214
for HIV-1 viral load without antiretroviral treatment, 291
of unintegrated circular HIV-1 DNA in peripheral mononuclear cells, 303
Prediction models, laboratory test results in, 442
Predictive factors, of cytomegalovirus infection and survival, 171
Pregnancy, in HIV infection course, 404
Pregnant women, HTLV-I infected (letter), 95
Prevalence, decline of in young women in Tanzania, 262
Prevention, economic evaluation of for gay and bisexual male adolescents, 83
Prison population, indeterminate HIV serology in, 376
Probenecid, pharmacokinetics of in HIV-infected subjects, 227
Proinflammatory cytokines, in HIV-associated wasting and HIV RNA levels, 411
Puerto Rico, risk behavior, HIV seropositivity and tuberculosis infection in injection drug users of, 477
Putrescine, in HIV-infected cells, 101

Quality of life, health-related, 433
Quality-adjusted life years, in gay and bisexual males, 83

Race, health services use and, 253
Reporting methods, for delay adjustment in AIDS surveillance data (letter), 182
Repression, HIV tat protein in, 9
Retinitis, cytomegalovirus, cidofovir for relapsing, 339
Retrovirus, in transfer for HLA-DR and CD25 to target cells, 196
Reverse transcriptase
codon 215 mutation of, 203
in Visna virus infection inhibition, 296
Reverse transcription, in HIV-1 RNA level analysis, 214
Risk behavior
in bisexual men, 361
of injecting drug users in Puerto Rican shooting galleries, 477
among injection drug users, 160
social context of, 368
Risk factors
for HIV seropositivity in drug users in treatment, 283
in prison population, 376
Russia, HTLV-I prevalence in patients with STDs in (letter), 97

S-adenosylmethionine decarboxylase, in HIV-infected cells, 101
Sanatorium, HTLV-I prevalence in leprosy patients in, 380
Selenocysteine insertion sequence (SECIS) elements, in HIV-1 strain HXB2, 398
Selenoproteins, viral encoding of, 398
Serology
of endemic HTLV-IIB infection in Venezuelan Indians, 458
for HIV-1 V3 subtypes, 156
indeterminate, in prison population, 376
Seropositivity
in drug users in treatment, 283
in injecting drug users in Puerto Rican shooting galleries, 477

Seroreactivity
to HIV-1 V3 subtypes A to H, 156
P-to-W substitution in V3 loop and (letter), 91
Serum total cholesterol, HIV infection and in high-risk men, 51
Sex partners, in Native American drug users, 275
Sexual behaviors
in bisexual men, 361
high-risk, in Native American drug users, 275
social context of, 368
in urban minority youth, 269
of women in Abidjan, 470
Sexually transmitted disease
HTLV-I prevalence with in Russia (letter), 97
incidence in Jamaica and Trinidad, 167
nonoxynol-9 for, 327
Shooting galleries, risk behavior, HIV seropositivity and tuberculosis infection in managers of, 477
Single-dose study, of stavudine penetration into cerebrospinal fluid, 235
Situational setting, unsafe sex and, 368
Sociodemographic factors, in unsafe sex, 368
Spermidine, in HIV-infected cells, 101
Spermine, in HIV-infected cells, 101
Squamous intraepithelial lesions, anal
in HIV-positive and -negative homosexual and bisexual men, 320
in HIV-positive and -negative homosexuals, 314
Stavudine, penetration into cerebrospinal fluid, 235
Substance abuse
in prison population, 376
social context of, 368
Survival
nucleoside analog drugs and, 239
predictive factors of cytomegalovirus and, 171
zidovudine and, 239
Swiss Collaborative HIV and Pregnancy Study, 404
Syphilis, in pregnant Japanese women with HTLV-I (letter), 95

T lymphocytes
chronically HIV infected, 112
counts, conservation of during HIV infection, 450
homeostasis of in HIV infection, 450
standard values of subsets in Africa (letter), 183, 184
unintegrated circular HIV-1 DNA and decline in, 303
Tanzania, declining HIV-1 infection prevalence in women of, 262
Tap-and-drain model, for HIV pathogenesis, 245
TAR domain, in HIV-1 replication inhibition, 104
Tat mimic, in HIV-1 replication inhibition, 104
Tat protein
RNA-binding, in HIV-1 replication inhibition, 104
for transactivation and repression of HIV transcription, 9
Tax/rex messenger RNA, in HIV-1/HTLV-I/II coinfection, 391
Testosterone, megestrol use in HIV-positive men and (letter), 179
Thailand, HIV-1 infection epidemiology in opiate users of, 73
Therapeutic agents, in HIV-1 replication inhibition, 104
Timm's stain, in FIV-infected cats, 1
Toxoplasma, in pregnant Japanese women with HTLV-I (letter), 95
Transactivation, HIV tat protein in, 9
Transcription
HIV-1, 17
HIV tat protein in transactivation and repression of, 9
Transmission
of CCR5 HIV-1 (letter), 180
in hemophilic patients, 42
maternal antibody titers against autologous virus and (letter), 92
Trinidad, HTLV-I-associated myelopathy/tropical spastic paraparesis in, 167
Tropical spastic paraparesis, incidence with HTLV-I in Jamaica and Trinidad, 167
Tuberculosis infection, in injecting drug users in Puerto Rican shooting galleries, 477

United States, declining HIV RNA viral loads in (letter), 186
Urban population
alcohol use and condom use in minority youth of, 269
health services use by, 253
Utilization, by urban women at risk for HIV-1 infection, 253

V3 loop
in serologic reactivity (letter), 91
seroreactivity to, 156
Vaccines, HIV-neutralizing antibodies and, 27
Vaginal infections, nonoxynol-9 for, 327
Vaginal microbicide, nonoxynol-9 as, 327
Venezuelan Indians, endemic HTLV-IIB infection in, 458
Vertical transmission
of CCR5 HIV-1 (letter), 180
maternal antibody titers against autologous virus and (letter), 92
Vietnam, risk factors for HIV seropositivity in drug users in, 283
Viral DNA, in HIV-1 infection, 303
Viral encoding, of selenoproteins, 398
Viral interference
in CD4 expression, 112
Epstein-Barr virus DNA and, 69
Viral load
autologous lymphocyte infusion effect on, 129
declining in United States (letter), 186
in hemophilic patients, 42
with HIV-1/HTLV-I/II coinfection, 391
susceptibility of PBMCs to apoptosis and, 419
without antiretroviral treatment, 291
Viral long terminal repeat (VTR)
HIV tat protein in transcriptional activation of, 9
sequence amplification of in determining HIV-neutralizing antibodies, 27
Virologic response, HIV-1 reverse transcriptase codon 215 mutation in, 203
Visna virus infection, dideoxynucleoside analog derivatives inhibiting, 296

Wasting, HIV RNA levels and, 411
Weight loss, in HIV-associated wasting and HIV RNA levels, 411
Women
declining HIV-1 infection prevalence in, 262
health services use by in urban areas, 253
HIV counseling and testing of, 470

Zidovudine
benefit of in HIV-infected patients, 345
immunologic and virologic responses to, 203
pharmacokinetics of in HIV-infected subjects, 227
survival and, 239